RecruitingNot ApplicableNCT04783103
Neuromodulation in the Elderly Depressed: a Brain Imaging Pilot Study
Neuromodulation in the Elderly Depressed: a Brain Im-aging Pilot Study
Sponsor
Universitair Ziekenhuis Brussel
Enrollment
44 participants
Start Date
May 7, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
To evaluate safety and efficacy of an accelerated deep brain Transcranial Magnetic stimulation (adTMS) and transcutaneous direct current stimulation (tDCS) protocol in an elderly depressed patient population
Eligibility
Min Age: 65 Years
Inclusion Criteria6
- • In- and outpatients (age 65 year or older).
- Meeting the Diagnostic and Statistical Manual of Mental Disorders (DSM 5) criteria for unipolar depression according 17-item Hamilton depression rating scale (HDRS-17) score of 17 or more.
- Failed to respond to at least one adequate course with an antidepressant medication trial, including the current one.
- Intention to continue the current (\>6 weeks) antidepressant treatment at a stable dose dur-ing the stimulation.
- Benzodiazepines are permitted up to a maximum dose of 40 mg diazepam or equivalent. If the dosage has been recently changed, it should be stable for at least 2 weeks.
- Able to read, understand and sign the Informed Consent Form.
Exclusion Criteria5
- • Psychosis (except depression with psychotic features).
- A personal history of seizures or epilepsy, a history of seizures or epilepsy in first degree relatives and the presence of any known factor that can lower the seizure threshold (sleep deprivation, substance abuse, etc.), previous head injury and the presence of metallic implants in the cephalic region (e.g., aneurysm clips, shunts, stimulators, cochlear implants, electrodes) with the exception of dental fillings. The presence of cardiac pacemakers, neurostimulators, surgical clips or other electronic equipment, comorbidity with the following neurological disorders: increased intracranial pressure, space-occupying lesion, history of stroke or transient ischemic attack, brain aneurysm and any structural brain damage with increased risk for epilepsy detected with (study related) MRI.
- Patients with cognitive disturbances or dementia (Mini Mental State) \< 24.
- Suicide attempt within 6 months before the start of the study or present high risk of suicide per the investigator's clinical judgment and indicative response\* on the Columbia-Suicide Severity Rating Scale (C-SSRS) and 21-items Beck Scale for Suicide Ideation (BSI). \*'yes' on Item 5 (active suicidal ideation with specific plan and intent).
- Any change in the habitual psychopharmacological agents will be considered as dropout.
Interventions
DEVICEa Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil
3 weeks home use
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04783103
Related Trials
A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
NCT070533456 locations
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
NCT0728466712 locations
CDK4/6 Inhibitors in Breast Cancer Elderly Patients: an Observational Ambispective Longitudinal Multicenter Study
NCT073998081 location
Accelerated vs. Conventional Theta Burst Stimulation for Late-life Depression
NCT068543672 locations
Effects of a Classic High-frequency rTMS Treatment Versus a Deep rTMS Treatment
NCT049560161 location